Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/IRCT2016041920441N4
IRCT2016041920441N4Completed未知

Omega-3 in the prevention of contrast-induced nephropathy after percutaneous coronary intervention

Shiraz University of Medical Sciences, international branch0 sites80 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
未知
Status
Completed
Sponsor
Enrollment
80
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 years to 80 years (—)
Sex
All

Inclusion Criteria

  • •Inclusion criteria included GFR more than 60 ml/min/1.73 m2; the ages of 18 to 80 years; patients undergoing elective PCI. Exclusion criteria: Pretreatment with N-acetyl cystein or intravenous vitamin C; sensitivity or tolerance to ASA or Clopidogrel or omega-3; sever adverse effects to drugs

Exclusion Criteria

  • Not provided

Investigators

Sponsor
Shiraz University of Medical Sciences, international branch

Similar Trials

Completed
Not Applicable
The role of Omega-3 polyunsaturated fatty acids in the prevention of contrast-induced nephropathy (CIN) after percutaneous coronary intervention (PCI) in chronic kidney disease (CKD) patientsrenal disease.Nephropathy induced by other drugs, medicaments and biological substances
IRCT2016031320441N3Vice chancellor for research, Shiraz University of Medical Sciences, International branch80
Completed
Not Applicable
Effect of omega 3 in the prevention of 30-days major adverse cardiovascular events following Carotid Stenting
IRCT2017011120441N6Shiraz University of Medical Sciences, Vice Chancellor of Research60
Recruiting
Not Applicable
Survey of the Effect of Omega-3 in the Prevention of Preeclampsia”
IRCT20210426051094N1Kurdistan University of Medical Sciences72
Not yet recruiting
Not Applicable
Omega-3 fish oil for the prevention of Gestational DiabetesGestational Diabetes
ACTRN12617000177358The University of Newcastle74
Active, not recruiting
Not Applicable
Omega-3 fatty acids for Prevention of post-opERative Atrial fibrillation (OPERA) - OPERAPatients scheduled for cardiac surgeryMedDRA version: 9.1Level: SOCClassification code 10007541
EUCTR2009-017582-29-ITCONSORZIO MARIO NEGRI SUD1,516